<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27962" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nail Psoriasis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Muneer</surname>
            <given-names>Hira</given-names>
          </name>
          <aff>Sandeman Provincial Hospital Quetta</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sathe</surname>
            <given-names>Nishad C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Masood</surname>
            <given-names>Sadia</given-names>
          </name>
          <aff>Aga Khan University Hospital karachi</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hira Muneer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nishad Sathe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sadia Masood declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27962.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Nail psoriasis&#x000a0;is a subtype of psoriasis, the common chronic inflammatory skin&#x000a0;condition&#x000a0;that can also affect the joints. Although&#x000a0;cutaneous manifestations of psoriasis are frequently observed, nail involvement significantly impacts patients' social and psychological well-being. This&#x000a0;activity comprehensively reviews the clinical presentation, evaluation, and treatment strategies for nail psoriasis, shedding light on the challenges posed by the slow growth pace of nails and the prolonged nature of treatment. The&#x000a0;session&#x000a0;emphasizes the crucial role of the interprofessional healthcare team in evaluating and treating patients with nail psoriasis, highlighting the need for collaborative approaches to enhance patient outcomes.&#x000a0;Learners will gain insights into the diverse clinical manifestations of nail psoriasis, including discoloration, hyperkeratosis, pitting, and onycholysis, equipping them with the knowledge to navigate the complexities of managing this condition. Educating clinicians on setting realistic patient expectations and fostering effective communication within the healthcare team are pivotal aspects addressed in this activity, aiming to improve the quality of care provided to individuals grappling with psoriasis of the nails.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Determine&#x000a0;the&#x000a0;etiology, pathophysiology, and exacerbating factors&#x000a0;of nail psoriasis.</p></list-item><list-item><p>Assess history and physical examination findings of&#x000a0;nail psoriasis.</p></list-item><list-item><p>Identify&#x000a0;the management options for&#x000a0;nail psoriasis according to the severity of the disease.</p></list-item><list-item><p>Coordinate the&#x000a0;interprofessional team to improve outcomes for patients with nail psoriasis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27962&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27962">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27962.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Psoriasis is a common chronic inflammatory skin condition; however, a subtype of psoriasis can include nail involvement, systemic involvement (eg, joints), or both nail and systemic involvement; nail psoriasis can be the first presentation of cutaneous psoriasis, a sequela&#x000a0;of cutaneous psoriasis, or a concurrent presentation of psoriasis.<xref ref-type="bibr" rid="article-27962.r1">[1]</xref>&#x000a0;Psoriatic involvement of the nail bed or nail matrix is the purported cause of nail psoriasis.<xref ref-type="bibr" rid="article-27962.r2">[2]</xref> Nail involvement is a visible indicator to predict&#x000a0;concomitant or future&#x000a0;inflammatory joint activity, most prominently in the distal interphalangeal joint, where psoriatic arthritis classically presents.<xref ref-type="bibr" rid="article-27962.r3">[3]</xref></p>
        <p>Nail psoriasis can manifest clinically as a wide variety of nail changes, like nail discoloration (eg, oil drops), subungual hyperkeratosis, pitting (ie, punctate nail depressions), and onycholysis (ie, distal nail plate separation from nail bed), depending&#x000a0;on the part of the nail unit affected (see <bold>Image</bold>. Nail Psoriasis). Patients with&#x000a0;nail psoriasis may have impaired quality of life due to the appearance of their nails, and significant morbidity and functional impairments may arise in&#x000a0;some cases.<xref ref-type="bibr" rid="article-27962.r4">[4]</xref><xref ref-type="bibr" rid="article-27962.r5">[5]</xref>&#x000a0;Nail psoriasis management is challenging since prolonged treatment is required and may not&#x000a0;be able to control disease activity entirely. Educating patients on the prognosis and outcomes of treatment is most important to set expectations and prepare for a successful treatment approach.<xref ref-type="bibr" rid="article-27962.r6">[6]</xref></p>
      </sec>
      <sec id="article-27962.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The exact etiology of nail psoriasis&#x000a0;is unclear, but multiple factors, including genetic, immunological, and environmental factors, may contribute to nail psoriasis.<xref ref-type="bibr" rid="article-27962.r1">[1]</xref>&#x000a0;Ultimately, nail matrix or nail bed inflammation&#x000a0;is implicated in nail psoriasis.&#x000a0;Dysregulation of innate immunity is putatively the&#x000a0;strongest associated factor.<xref ref-type="bibr" rid="article-27962.r7">[7]</xref> However, some genetic factors, like human leukocyte antigens (Cw6, B13, B17), are associated with nail psoriasis, and family history is often significant in individuals with nail psoriasis, suggesting a genetic or inherited basis;&#x000a0;however, this is incompletely understood.<xref ref-type="bibr" rid="article-27962.r8">[8]</xref></p>
      </sec>
      <sec id="article-27962.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Nail psoriasis affects both children and adults, affecting both males and females equally, with increasing prevalence with increasing age.<xref ref-type="bibr" rid="article-27962.r9">[9]</xref><xref ref-type="bibr" rid="article-27962.r10">[10]</xref>&#x000a0;Nail psoriasis mostly develops in association with cutaneous psoriasis and psoriatic arthritis, with&#x000a0;studies varying widely on their prevalence; however, a strong association of 80% to 90% between psoriatic arthritis and nail psoriasis is found across multiple studies, likely because psoriatic arthritis classically affects the distal interphalangeal joint, which is the joint closest to the nail.<xref ref-type="bibr" rid="article-27962.r11">[11]</xref> Nail psoriasis may develop as a sole manifestation of psoriasis or concurrently with other symptoms or after the onset of cutaneous symptoms.<xref ref-type="bibr" rid="article-27962.r6">[6]</xref></p>
      </sec>
      <sec id="article-27962.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Nail psoriasis usually results from psoriatic inflammation involving the nail bed or nail matrix.<xref ref-type="bibr" rid="article-27962.r12">[12]</xref> The nail matrix is mainly responsible for nail plate formation and is located beneath the proximal nail fold. The superficial part of the nail plate is formed from the proximal nail matrix, while the deep part is formed from the distal nail matrix.&#x000a0;Clinical features related to nail matrix involvement are nail pitting, red spots in the lunula, leukonychia, and crumbling of the complete nail plate.<xref ref-type="bibr" rid="article-27962.r13">[13]</xref> The nail bed lies directly beneath the nail plate and plays a significant role in the adherence of the nail plate to the nail bed.<xref ref-type="bibr" rid="article-27962.r14">[14]</xref>&#x000a0;The involvement of the nail bed manifests clinically as onycholysis, splinter hemorrhages, subungual hyperkeratosis, and&#x000a0;oil-drop discoloration.<xref ref-type="bibr" rid="article-27962.r2">[2]</xref><xref ref-type="bibr" rid="article-27962.r15">[15]</xref></p>
        <p>Genetic contributions to the formation of nail psoriasis are still uncertain but are likely significant given the high prevalence of psoriasis within a single family.<xref ref-type="bibr" rid="article-27962.r16">[16]</xref> Psoriatic nail disease may, however, align more closely with innate immunity dysregulation.&#x000a0;Psoriatic nail disease&#x000a0;may correlate with dysregulation of the immune system differently from disease limited to the skin, but this is poorly understood.</p>
      </sec>
      <sec id="article-27962.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathological findings of nail psoriasis are similar to cutaneous psoriasis, including mild-to-moderate hyperkeratosis, focal parakeratosis&#x000a0;(which is responsible for nail pitting), and spongiosis.<xref ref-type="bibr" rid="article-27962.r17">[17]</xref> Other prominent features are a neutrophilic inflammatory infiltrate, hypergranulosis, and&#x000a0;psoriasiform epidermal hyperplasia.<xref ref-type="bibr" rid="article-27962.r18">[18]</xref>&#x000a0;The papillary dermis in affected skin&#x000a0;contains&#x000a0;dilated, tortuous capillaries, while the&#x000a0;hyponychium shows the loss of the granular layer&#x000a0;with&#x000a0;hypergranulosis in the nail bed and nail matrix.<xref ref-type="bibr" rid="article-27962.r14">[14]</xref></p>
      </sec>
      <sec id="article-27962.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Because nail psoriasis can be associated with cutaneous and systemic findings (eg, psoriatic arthritis), a thorough history and physical should be performed&#x000a0;in patients with nail psoriasis.&#x000a0;</p>
        <p>
<bold>History</bold>
</p>
        <p>A thorough history of the nail findings consistent with psoriasis should be explored, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Onset</p>
          </list-item>
          <list-item>
            <p>Location (eg, number of nails involved or quadrants of nails involved)</p>
          </list-item>
          <list-item>
            <p>Duration</p>
          </list-item>
          <list-item>
            <p>Other patterns</p>
          </list-item>
          <list-item>
            <p>Joint symptoms (eg, swelling, pain, timing, onset, duration)</p>
          </list-item>
          <list-item>
            <p>Social history (eg, smoking)</p>
          </list-item>
          <list-item>
            <p>Medical history (eg, heart disease, metabolic disease, psoriasis)</p>
          </list-item>
          <list-item>
            <p>Family history (eg, history of psoriasis)</p>
          </list-item>
          <list-item>
            <p>Recent infections&#x000a0;<xref ref-type="bibr" rid="article-27962.r19">[19]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>Physical examination should focus on identifying the characteristic findings of nail psoriasis (see <bold>Image</bold>. Nail Pitting). Nail pitting is commonly seen in patients with psoriasis. The disease may affect&#x000a0;1 or more nails of the hands or feet, and this number should be noted as it is relevant for treatment. There may be&#x000a0;1 or more findings, which can include:<xref ref-type="bibr" rid="article-27962.r20">[20]</xref><xref ref-type="bibr" rid="article-27962.r21">[21]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pitting:</bold> Studded depressions in the nail plate</p>
          </list-item>
          <list-item>
            <p><bold>Subungual hyperkeratosis:</bold>&#x000a0;White keratin debris overlying the nail bed</p>
          </list-item>
          <list-item>
            <p><bold>Onycholysis: </bold>Distal separation of the nail plate from the underlying nail bed)</p>
          </list-item>
          <list-item>
            <p><bold>Oil-drop discoloration:&#x000a0;</bold>Pink macule or patch&#x000a0;(usually appearing on the proximal nail)&#x000a0;or red, discolored spots&#x000a0;on the lunula</p>
          </list-item>
          <list-item>
            <p><bold>Nail crumbling:</bold>&#x000a0;Disintegration of the distal nail</p>
          </list-item>
          <list-item>
            <p><bold>Leukonychia:</bold>&#x000a0;White lines on the nail plate</p>
          </list-item>
          <list-item>
            <p><bold>Splinter hemorrhages: </bold>Red, linear streaks on the nail</p>
          </list-item>
        </list>
        <p>Patients can also have other&#x000a0;manifestations of nail psoriasis, such as onychorrhexis, trachyonychia, or Beau lines, but these are less&#x000a0;characteristic and may indicate many other inflammatory or infectious findings.<xref ref-type="bibr" rid="article-27962.r22">[22]</xref>&#x000a0;Other than the nails, a thorough full-body skin examination should be performed to evaluate the coexistence of cutaneous psoriasis. Common areas affected classically in psoriasis include the extensor surfaces, anogenital area, and scalp.<xref ref-type="bibr" rid="article-27962.r23">[23]</xref><xref ref-type="bibr" rid="article-27962.r14">[14]</xref>&#x000a0;</p>
        <p>Other physical examination maneuvers should include inspection&#x000a0;and palpation of any affected joints, such as the distal interphalangeal joints; in some cases, bedside ultrasound can be used to better characterize the joint and nail disease.<xref ref-type="bibr" rid="article-27962.r24">[24]</xref>&#x000a0;In combination, the presence of one or more nails with characteristic findings, possible skin involvement, and possible systemic symptoms can be collectively used to evaluate the extent of the disease.&#x000a0;</p>
      </sec>
      <sec id="article-27962.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Nail psoriasis can be diagnosed based on a thorough history and physical examination. The exclusion of fungal nail disease is important as onychomycosis can appear clinically indistinct from nail psoriasis.<xref ref-type="bibr" rid="article-27962.r9">[9]</xref>&#x000a0;A periodic acid-Schiff stain of a nail clipping, potassium hydroxide (KOH) stain of nail clippings, or a fungal culture can be used to rule out onychomycosis. However, the presence of onychomycosis should not immediately rule out the possibility of coexisting nail psoriasis; instead, after treatment of onychomycosis, the patient should be evaluated for resolution of the fungal nail disease and should later be examined for any nail, skin, or systemic findings suspicious for nail psoriasis.<xref ref-type="bibr" rid="article-27962.r25">[25]</xref>&#x000a0;Ultrasound may be used as an adjunctive evaluation method in some patients, but this is not required and is under study as a tool for psoriatic arthritis.<xref ref-type="bibr" rid="article-27962.r26">[26]</xref>&#x000a0;A nail biopsy is generally unnecessary, but in cases with significant diagnostic uncertainty, a biopsy of the nail matrix or nail bed may be used in histopathologic examination to identify the characteristic findings of psoriasis.<xref ref-type="bibr" rid="article-27962.r27">[27]</xref></p>
      </sec>
      <sec id="article-27962.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment of nail psoriasis can include topical or systemic therapy, which is based on the severity or extent of disease; mild disease (ie, disease limited to 1 or 2 nails with no functional impairment or systemic involvement) can usually be treated with topical therapy,&#x000a0;whereas moderate-to-severe disease (ie, disease beyond 2 nails or disease with functional impairment or systemic involvement) may require initiating systemic therapy.<xref ref-type="bibr" rid="article-27962.r10">[10]</xref>&#x000a0;There are myriad options for systemic treatment, including biologic agents, phototherapy, intense pulsed light, lasers,&#x000a0;and photodynamic therapy.&#x000a0;The factors&#x000a0;that need to be considered for treatment options are the age of the patient, comorbidities, relative or absolute contraindications to therapy, concomitant skin and joint involvement, impact on quality of life, patient preference, and cost of treatment.<xref ref-type="bibr" rid="article-27962.r28">[28]</xref></p>
        <p>
<bold>Mild Disease</bold>
</p>
        <p>For mild disease, high-potency topical corticosteroids and topical vitamin D analogs (eg, calcipotriol) are recommended twice daily on the affected nails, alone or together. However, some studies have shown improved use by patients&#x000a0;with a combined&#x000a0;topical betamethasone diproprionate and calcipotriol therapy; these have been used as a topical therapy with success as a combined or separate solution or foam, and the combined foam was used in 1 study following ablative fractionated laser as a pretreatment with successful results.<xref ref-type="bibr" rid="article-27962.r5">[5]</xref><xref ref-type="bibr" rid="article-27962.r29">[29]</xref>&#x000a0;</p>
        <p>When topical therapy is unsuccessful with topical corticosteroids and topical vitamin D analogs, other therapies to consider may include topical tacrolimus and topical tazarotene.<xref ref-type="bibr" rid="article-27962.r30">[30]</xref> Fractionated CO<sub>2</sub> laser has been used with tazarotene for nail psoriasis with success in at least 1 study.<xref ref-type="bibr" rid="article-27962.r31">[31]</xref>&#x000a0;Topical tofacitinib, a modulator of the janus kinase family, has shown some promise as a 2% solution for recalcitrant nail psoriasis.<xref ref-type="bibr" rid="article-27962.r32">[32]</xref>&#x000a0;When these therapies are unsuccessful or are otherwise contraindicated, intralesional corticosteroids may be considered, or systemic therapy, as used for moderate-to-severe disease, may need to be considered.<xref ref-type="bibr" rid="article-27962.r33">[33]</xref></p>
        <p>
<bold>Moderate-to-Severe Disease</bold>
</p>
        <p>For moderate-to-severe nail psoriasis, with significant disease severity or extent, first-line therapy should include a biologic agent where feasible and not contraindicated.<xref ref-type="bibr" rid="article-27962.r34">[34]</xref><xref ref-type="bibr" rid="article-27962.r35">[35]</xref>&#x000a0;Biologic agents have significantly improved nail psoriasis across multiple studies.<xref ref-type="bibr" rid="article-27962.r36">[36]</xref> A network meta-analysis of multiple biologic agents has shown that at 24&#x000a0;to 28 weeks, ixekizumab, followed by brodalumab and bimekizumab, was most efficacious for complete resolution of nail psoriasis, whereas at weeks 48&#x000a0;to 52, ixekizumab, followed by adalimumab and brodalumab,&#x000a0;had the highest absolute probability to achieve complete resolution of&#x000a0;nail psoriasis.<xref ref-type="bibr" rid="article-27962.r37">[37]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Tumor necrosis factor-&#x003b1; inhibitors</bold> (eg, adalimumab, infliximab, etanercept, certolizumab, golimumab): Adalimumab was shown to be efficacious in multiple studies for nail psoriasis, though it has been outperformed in other studies by guselkumab and ixekizumab.<xref ref-type="bibr" rid="article-27962.r36">[36]</xref><xref ref-type="bibr" rid="article-27962.r38">[38]</xref>&#x000a0;Similar data have been observed for the class of medications being successful for the treatment of nail psoriasis across other studies.<xref ref-type="bibr" rid="article-27962.r36">[36]</xref><xref ref-type="bibr" rid="article-27962.r39">[39]</xref><xref ref-type="bibr" rid="article-27962.r40">[40]</xref><xref ref-type="bibr" rid="article-27962.r41">[41]</xref><xref ref-type="bibr" rid="article-27962.r42">[42]</xref><xref ref-type="bibr" rid="article-27962.r43">[43]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Interleukin-17 inhibitors</bold> (eg, secukinumab, ixekizumab, brodalumab): Secukinumab has been shown to provide sustained treatment&#x000a0;for patients with nail psoriasis.<xref ref-type="bibr" rid="article-27962.r44">[44]</xref>&#x000a0;Brodalumab has been shown to be efficacious in an open-label study.<xref ref-type="bibr" rid="article-27962.r45">[45]</xref>&#x000a0;Meanwhile, ixekizumab, which is dosed every 4 weeks, has been shown to be the most efficacious treatment when compared across multiple biologic agents.<xref ref-type="bibr" rid="article-27962.r37">[37]</xref><xref ref-type="bibr" rid="article-27962.r46">[46]</xref><xref ref-type="bibr" rid="article-27962.r47">[47]</xref>&#x000a0;The interleukin-17 inhibitors should be avoided in patients with active hepatitis infection and active inflammatory bowel disease, while brodalumab should be avoided in patients with recent&#x000a0;suicidality.<xref ref-type="bibr" rid="article-27962.r48">[48]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Interleukin-23 inhibitors</bold> (eg, guselkumab, risankizumab, tildrakizumab): In a subset of patients with psoriatic arthritis, nail psoriasis severity indices improved significantly with guselkumab versus placebo at week 16 and at week 24.<xref ref-type="bibr" rid="article-27962.r49">[49]</xref>&#x000a0;Risankizumab, which is dosed every 12 weeks, has also been shown to be efficacious for nail psoriasis endpoints in a randomized controlled trial,&#x000a0;whereas tildrakizumab has been supported through individual cases and in other forms of psoriasis.<xref ref-type="bibr" rid="article-27962.r50">[50]</xref><xref ref-type="bibr" rid="article-27962.r51">[51]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Interleukin-12 and interleukin-23 inhibitors</bold> (eg, ustekinumab): Ustekinumab was shown to improve nail psoriasis in patients with moderate-to-severe psoriasis in one study, and it has been used for psoriasis across populations.<xref ref-type="bibr" rid="article-27962.r52">[52]</xref><xref ref-type="bibr" rid="article-27962.r53">[53]</xref></p>
          </list-item>
        </list>
        <p>If moderate-to-severe nail psoriasis does not improve after biologic agent use, even after switching between classes, or if biologic agent use is not feasible or contraindicated, second-line treatment can include methotrexate (oral or intralesional), apremilast, intralesional corticosteroids, topical therapies used in mild disease, or pulsed dye laser.<xref ref-type="bibr" rid="article-27962.r54">[54]</xref><xref ref-type="bibr" rid="article-27962.r55">[55]</xref><xref ref-type="bibr" rid="article-27962.r56">[56]</xref><xref ref-type="bibr" rid="article-27962.r57">[57]</xref>&#x000a0;Although these&#x000a0;therapies have been shown to be efficacious, additional therapies for consideration&#x000a0;include tofacitinib (oral or topical), acitretin, cyclosporine, fractional CO<sub>2</sub> laser, excimer laser, and narrowband ultraviolet B phototherapy.<xref ref-type="bibr" rid="article-27962.r32">[32]</xref><xref ref-type="bibr" rid="article-27962.r58">[58]</xref><xref ref-type="bibr" rid="article-27962.r59">[59]</xref><xref ref-type="bibr" rid="article-27962.r60">[60]</xref></p>
      </sec>
      <sec id="article-27962.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Many conditions need to be distinguished from nail psoriasis. Because nail dystrophy and other characteristic findings in nail psoriasis can be found in other disease states, distinguishing these can be challenging. For instance, age-related changes from trauma, vascular lower extremity diseases&#x000a0;(eg, peripheral artery disease, chronic venous stasis, trauma),&#x000a0;and peripheral neuropathy can cause nail changes that may be confused for nail psoriasis; however,&#x000a0;these findings&#x000a0;will be unlikely to show other findings of psoriasis if they are&#x000a0;the cause of nail changes.<xref ref-type="bibr" rid="article-27962.r13">[13]</xref>&#x000a0;Many medications can also cause nail changes, so ruling out medication changes is essential.<xref ref-type="bibr" rid="article-27962.r13">[13]</xref>&#x000a0;Some other pertinent differential diagnoses with nail changes most similar to nail psoriasis are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Onychomycosis:</bold> The changes of onychomycosis resemble nail psoriasis; sometimes, it is difficult to distinguish between the two. Nail pitting, onycholysis, and the oil drop sign (ie, discoloration of the nail) are the main features of nail psoriasis and are less likely to be found in onychomycosis. Onychomycosis can be diagnosed by fungal culture or nail clipping analysis with periodic acid-Schiff (PAS)&#x000a0;or potassium hydroxide (KOH) preparations.<xref ref-type="bibr" rid="article-27962.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Alopecia areata:</bold> The nail changes of alopecia areata can vary and include trachyonychia, linear ridging, nail pitting, nail fissuring, or other nail abnormalities with nonscarring patchy alopecia, typically on the scalp.<xref ref-type="bibr" rid="article-27962.r61">[61]</xref><xref ref-type="bibr" rid="article-27962.r62">[62]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Lichen planus:</bold> Nail involvement presents as thinning of the nails with ridges and grooves of the nail plate, which can scar&#x000a0;the&#x000a0;cuticle and lead to pterygium formation. Lichen planus also often involves the mucosa or skin with characteristic pruritic, purple, and polygonal papules or plaques.<xref ref-type="bibr" rid="article-27962.r63">[63]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Pityriasis rubra pilaris:</bold>&#x000a0;Though nail changes in pityriasis rubra pilaris can include thickened nails with splinter hemorrhages, which are less common findings in nail psoriasis, the cutaneous findings of this disease can be similar to those in psoriasis. Skin findings in pityriasis rubra pilaris, though, will usually include&#x000a0;hyperkeratotic follicular papules, orange-red plaques with fine scales, and hyperkeratosis of the palms and soles.<xref ref-type="bibr" rid="article-27962.r9">[9]</xref><xref ref-type="bibr" rid="article-27962.r64">[64]</xref></p>
          </list-item>
        </list>
        <p>Many other dermatologic conditions may also present with nail findings that can overlap with nail psoriasis, including atopic dermatitis, Darier disease, and Hailey-Hailey disease. These conditions should also be considered when evaluating a patient with nail changes.<xref ref-type="bibr" rid="article-27962.r13">[13]</xref></p>
      </sec>
      <sec id="article-27962.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with nail psoriasis have a chronic and protracted course with periods of improvement and worsening, which can impact quality of life. Patients&#x000a0;with nail psoriasis&#x000a0;may have more difficulty with treatment and thus poorer disease control, since there are limited data on treatments compared with cutaneous psoriasis.<xref ref-type="bibr" rid="article-27962.r65">[65]</xref>&#x000a0;Worsening of nail disease may occur due to nail trauma, which is often unavoidable, due to koebnerization. However, treatment with topical&#x000a0;or systemic agents for mild and moderate-to-severe disease, respectively,&#x000a0;may alter the disease process, though with some concern for adverse effects.<xref ref-type="bibr" rid="article-27962.r66">[66]</xref></p>
      </sec>
      <sec id="article-27962.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The patient&#x000a0;with nail psoriasis may develop complications due to the disease process or&#x000a0;medications used&#x000a0;for treatment. The major complications can be grouped into functional disability, psychological distress, and infections, including bacterial (eg, paronychia) and fungal infections (eg, onychomycosis).</p>
      </sec>
      <sec id="article-27962.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Nail psoriasis is a chronic disease process; treatment may be prolonged,&#x000a0;so patient education to set expectations&#x000a0;is essential.<xref ref-type="bibr" rid="article-27962.r67">[67]</xref>&#x000a0;Patients should be educated that toenails take approximately 12 months to grow fully,&#x000a0;whereas fingernails take almost 6 months, so changes to nails before and after treatment will occur slowly. Therefore, photographs of the patient's nails should be taken and stored to monitor changes. Patients should avoid trauma to their nails, since koebnerization may worsen the disease. Patients may need to consider wearing gloves when handling chemicals or moisture, and their hands should be kept dry, other than emollient use. Nails should be kept neat, trimmed, and clean, particularly when onycholysis is present, as this can introduce microorganisms that lead to infection. Although psoriasis is usually associated with decreased infection, patients should be aware of the risk of infection, especially onychomycosis.</p>
      </sec>
      <sec id="article-27962.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Nail psoriasis is a difficult condition to manage, and its management is best done by an interprofessional team.<xref ref-type="bibr" rid="article-27962.r2">[2]</xref>&#x000a0;Nail psoriasis can be disfiguring and lead to distress or anxiety, particularly for patients who may need to display their nails&#x000a0;for their personal or professional lives (eg, hand model). The healthcare team can aid in recognizing anxiety or psychiatric issues and initiating appropriate referrals in this case. Pharmacists should be involved in educating patients on the appropriate use of topical and systemic medications since topical medications will need to be applied in a particular fashion to ensure the medication reaches the hyponychium, whereas systemic agents may require self-injection. Since nail psoriasis is strongly linked to psoriatic arthritis, a team-based approach with other&#x000a0;specialists may be needed.&#x000a0;Although nail psoriasis can be managed by a primary care provider, a referral to a dermatology specialist is most prudent to provide appropriate counseling, education, diagnosis, treatment, and monitoring. Close communication between interprofessional team members is vital to achieving desired outcomes in nail psoriasis.<xref ref-type="bibr" rid="article-27962.r14">[14]</xref></p>
      </sec>
      <sec id="article-27962.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27962&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27962">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/nail-psoriasis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27962">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27962/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27962">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-27962.s16">
        <fig id="article-27962.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Nail Psoriasis <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nail__psoriasis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-27962.s17">
        <fig id="article-27962.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Nail Pitting. Nail pitting is commonly seen in patients with psoriasis. Contributed by Lawrence Brent, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JPsA_Nail__pitting-1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-27962.s18">
        <title>References</title>
        <ref id="article-27962.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loo</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Tee</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Faheem</surname>
                <given-names>NAA</given-names>
              </name>
              <name>
                <surname>Yong</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Pok</surname>
                <given-names>LSL</given-names>
              </name>
              <name>
                <surname>Yahya</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Predictive factors of psoriatic arthritis in a diverse population with psoriasis.</article-title>
            <source>J Int Med Res</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>3000605231221014</fpage>
            <pub-id pub-id-type="pmid">38206198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jendoubi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ben Lagha</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rabhi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Doss</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mrabet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jaber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dhaoui</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Nail Involvement in Psoriatic Patients and Association with Onychomycosis: Results from a Cross-Sectional Study Performed in a Military Hospital in Tunisia.</article-title>
            <source>Skin Appendage Disord</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>299</fpage>
            <page-range>299-303</page-range>
            <pub-id pub-id-type="pmid">31559254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antony</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Allard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rambojun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lovell</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Shaddick</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jadon</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cavill</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Korendowych</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McHugh</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Tillett</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Psoriatic Nail Dystrophy Is Associated with Erosive Disease in the Distal Interphalangeal Joints in Psoriatic Arthritis: A Retrospective Cohort Study.</article-title>
            <source>J Rheumatol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>46</volume>
            <issue>9</issue>
            <fpage>1097</fpage>
            <page-range>1097-1102</page-range>
            <pub-id pub-id-type="pmid">30824637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strober</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Duffin</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sima</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Janak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Photowala</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bagel</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2024</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>2287401</fpage>
            <pub-id pub-id-type="pmid">38073528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laheru</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Antony</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carneiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Lernia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Love</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Del Rocio Macias Garcia</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mendon&#x000e7;a</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Olteanu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Perez-Chada</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Tannenbaum</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yazbek</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.</article-title>
            <source>J Rheumatol</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>433</fpage>
            <page-range>433-437</page-range>
            <pub-id pub-id-type="pmid">36319021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Egeberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>See</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Garrelts</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burge</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort.</article-title>
            <source>BMC Dermatol</source>
            <year>2020</year>
            <month>May</month>
            <day>20</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <pub-id pub-id-type="pmid">32434510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hile</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kahlenberg</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gudjonsson</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Recent genetic advances in innate immunity of psoriatic arthritis.</article-title>
            <source>Clin Immunol</source>
            <year>2020</year>
            <month>May</month>
            <volume>214</volume>
            <fpage>108405</fpage>
            <pub-id pub-id-type="pmid">32247832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pouw</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Leijten</surname>
                <given-names>EFA</given-names>
              </name>
              <name>
                <surname>Tekstra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Balak</surname>
                <given-names>DMW</given-names>
              </name>
              <name>
                <surname>Radstake</surname>
                <given-names>TRDJ</given-names>
              </name>
            </person-group>
            <article-title>[Spectrum of psoriatic conditions].</article-title>
            <source>Ned Tijdschr Geneeskd</source>
            <year>2019</year>
            <month>Jul</month>
            <day>29</day>
            <volume>163</volume>
            <pub-id pub-id-type="pmid">31361418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Satasia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sutaria</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Nail Whispers Revealing Dermatological and Systemic Secrets: An Analysis of Nail Disorders Associated With Diverse Dermatological and Systemic Conditions.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>9</issue>
            <fpage>e45007</fpage>
            <pub-id pub-id-type="pmid">37701161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garner</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Hoy</surname>
                <given-names>KDS</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Psoriasis: Recognition and Management Strategies.</article-title>
            <source>Am Fam Physician</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>562</fpage>
            <page-range>562-573</page-range>
            <pub-id pub-id-type="pmid">38215417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pala</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meliko&#x0011f;lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kara&#x0015f;ahin</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>Alkan Meliko&#x0011f;lu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The Frequency of Association of Nail Involvement and Psoriatic Arthritis in Psoriasis Patients.</article-title>
            <source>Eurasian J Med</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>55</volume>
            <issue>2</issue>
            <fpage>158</fpage>
            <page-range>158-164</page-range>
            <pub-id pub-id-type="pmid">37403914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Canal-Garc&#x000ed;a</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bosch-Amate</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Belinch&#x000f3;n</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Puig</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Nail Psoriasis.</article-title>
            <source>Actas Dermosifiliogr</source>
            <year>2022</year>
            <month>May</month>
            <volume>113</volume>
            <issue>5</issue>
            <fpage>481</fpage>
            <page-range>481-490</page-range>
            <pub-id pub-id-type="pmid">35697407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haneke</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.</article-title>
            <source>Psoriasis (Auckl)</source>
            <year>2017</year>
            <volume>7</volume>
            <fpage>51</fpage>
            <page-range>51-63</page-range>
            <pub-id pub-id-type="pmid">29387608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wanniang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Navya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ghodge</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Comparative Study of Clinical and Dermoscopic Features in Nail Psoriasis.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2020</year>
            <season>Jan-Feb</season>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-40</page-range>
            <pub-id pub-id-type="pmid">32055506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mendon&#x000e7;a</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Aydin</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>D'Agostino</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>The use of ultrasonography in the diagnosis of nail disease among patients with psoriasis and psoriatic arthritis: a systematic review.</article-title>
            <source>Adv Rheumatol</source>
            <year>2019</year>
            <month>Sep</month>
            <day>05</day>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <pub-id pub-id-type="pmid">31488208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Leng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>X</given-names>
              </name>
              <collab>Chinese Registry of Psoriatic Arthritis (CREPAR)</collab>
            </person-group>
            <article-title>Associations between family history of psoriatic disease and clinical characteristics on patients with psoriatic arthritis: a nationwide study from the Chinese Registry of Psoriatic Arthritis (CREPAR II).</article-title>
            <source>Clin Exp Rheumatol</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>41</volume>
            <issue>9</issue>
            <fpage>1901</fpage>
            <page-range>1901-1907</page-range>
            <pub-id pub-id-type="pmid">37199179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chau</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Parsi</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Ogawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kiuru</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Konia</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Psoriasis or not? Review of 51 clinically confirmed cases reveals an expanded histopathologic spectrum of psoriasis.</article-title>
            <source>J Cutan Pathol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>12</issue>
            <fpage>1018</fpage>
            <page-range>1018-1026</page-range>
            <pub-id pub-id-type="pmid">28833447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Vaccine-induced erythrodermic psoriasis in a child successfully treated with secukinumab: A case report and brief literature review.</article-title>
            <source>Dermatol Ther</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>9</issue>
            <fpage>e15684</fpage>
            <pub-id pub-id-type="pmid">35789520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dopytalska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sobolewski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>B&#x00142;aszczak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Szyma&#x00144;ska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Walecka</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Psoriasis in special localizations.</article-title>
            <source>Reumatologia</source>
            <year>2018</year>
            <volume>56</volume>
            <issue>6</issue>
            <fpage>392</fpage>
            <page-range>392-398</page-range>
            <pub-id pub-id-type="pmid">30647487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Subudhi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jena</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mohanty</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Panda</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Study of Clinical and Dermoscopic Features in Nails of Papulosquamous Disorders and their Correlation with Disease Severity: A Cross-Sectional Study.</article-title>
            <source>Indian J Dermatol</source>
            <year>2022</year>
            <season>Sep-Oct</season>
            <volume>67</volume>
            <issue>5</issue>
            <fpage>488</fpage>
            <page-range>488-494</page-range>
            <pub-id pub-id-type="pmid">36865867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bian</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Huo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Nail psoriasis in China: A prospective multicentre study.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>549</fpage>
            <page-range>549-556</page-range>
            <pub-id pub-id-type="pmid">38100231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Preda-Naumescu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Penney</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pearlman</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Brodell</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Nahar</surname>
                <given-names>VK</given-names>
              </name>
            </person-group>
            <article-title>Nail Manifestations in COVID-19: Insight into a Systemic Viral Disease.</article-title>
            <source>Skin Appendage Disord</source>
            <year>2021</year>
            <month>Aug</month>
            <day>17</day>
            <volume>183</volume>
            <issue>6</issue>
            <fpage>1</fpage>
            <page-range>1-6</page-range>
            <pub-id pub-id-type="pmid">34580633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rusk</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Fleischer</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>In psoriasis treatment, greater improvement in skin severity predicts greater improvement in nail severity.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>32</volume>
            <issue>8</issue>
            <fpage>894</fpage>
            <page-range>894-897</page-range>
            <pub-id pub-id-type="pmid">31971034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michelucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Salvia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Granieri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Manzo Margiotta</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Panduri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morganti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Romanelli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Assessment and Monitoring of Nail Psoriasis with Ultra-High Frequency Ultrasound: Preliminary Results.</article-title>
            <source>Diagnostics (Basel)</source>
            <year>2023</year>
            <month>Aug</month>
            <day>21</day>
            <volume>13</volume>
            <issue>16</issue>
            <pub-id pub-id-type="pmid">37627974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dharmian</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Sathiyaseelan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Renganathan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mubees</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Naser</surname>
                <given-names>MYA</given-names>
              </name>
              <name>
                <surname>Ramkrishnan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Arumugam</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology and Management of Onychomycosis and Novel Approaches for Effective Transdermal Applications.</article-title>
            <source>Int J Pharm Compd</source>
            <year>2023</year>
            <season>Nov-Dec</season>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>494</fpage>
            <page-range>494-502</page-range>
            <pub-id pub-id-type="pmid">38100667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azuaga</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Cuervo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Celis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Frade-Sosa</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sarmiento-Monroy</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ruiz-Esquide</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Puerta</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sanmart&#x000ed;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ram&#x000ed;rez</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Synovial tissue features associated with poor prognosis in inflammatory arthritis.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2024</year>
            <month>Jan</month>
            <day>10</day>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">38200561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaya &#x00130;slamo&#x0011f;lu</surname>
                <given-names>ZG</given-names>
              </name>
              <name>
                <surname>Uysal</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Demirba&#x0015f;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x00130;slamo&#x0011f;lu</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Evaluating nail thickness and stiffness with shear-wave elastography in nail psoriasis: A preliminary study.</article-title>
            <source>Skin Res Technol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-49</page-range>
            <pub-id pub-id-type="pmid">31338888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanna</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Galluzzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zangrilli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bavetta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Campione</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>531</fpage>
            <page-range>531-534</page-range>
            <pub-id pub-id-type="pmid">32419527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ortner</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Mandel</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Skak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zibert</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bourlioux</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nissen</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>CSK</given-names>
              </name>
              <name>
                <surname>Philipsen</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Haedersdal</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Investigating the efficacy and safety of calcipotriol/betamethasone dipropionate foam and laser microporation for psoriatic nail disease-A hybrid trial using a smartphone application, optical coherence tomography, and patient-reported outcome measures.</article-title>
            <source>Dermatol Ther</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>12</issue>
            <fpage>e15965</fpage>
            <pub-id pub-id-type="pmid">36321647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torsekar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gautam</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Topical Therapies in Psoriasis.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2017</year>
            <season>Jul-Aug</season>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>235</fpage>
            <page-range>235-245</page-range>
            <pub-id pub-id-type="pmid">28761838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Essa Abd Elazim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mahmoud Abdelsalam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mohamed Awad</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of combined fractional carbon dioxide laser and topical tazarotene in nail psoriasis treatment: A randomized intrapatient left-to-right study.</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>7</issue>
            <fpage>2808</fpage>
            <page-range>2808-2816</page-range>
            <pub-id pub-id-type="pmid">34664357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berbert Ferreira</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berbert Ferreira</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Neves Neto</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Caparroz-Assef</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Brichta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Damiani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Iorizzo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Topical Tofacitinib as Effective Therapy in Patients with Plaque Psoriasis Responsive to Systemic Drugs but with Resistant Nail Psoriasis.</article-title>
            <source>Skin Appendage Disord</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>380</fpage>
            <page-range>380-384</page-range>
            <pub-id pub-id-type="pmid">37900775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iorizzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gioia Di Chiacchio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Di Chiacchio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Grover</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lipner</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Richert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Piraccini</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Starace</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tosti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Intralesional steroid injections for inflammatory nail dystrophies in the pediatric population.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2023</year>
            <season>Jul-Aug</season>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>759</fpage>
            <page-range>759-761</page-range>
            <pub-id pub-id-type="pmid">36939031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hanada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kawaguchi</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Patient preference for biologic treatments of psoriasis in Japan.</article-title>
            <source>J Dermatol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>46</volume>
            <issue>6</issue>
            <fpage>466</fpage>
            <page-range>466-477</page-range>
            <pub-id pub-id-type="pmid">30985030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanna</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zangrilli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bavetta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Campione</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of adalimumab in difficult-to-treat psoriasis.</article-title>
            <source>Dermatol Ther</source>
            <year>2020</year>
            <month>May</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>e13374</fpage>
            <pub-id pub-id-type="pmid">32246516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hwang</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Ricardo</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Lipner</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>695</fpage>
            <page-range>695-720</page-range>
            <pub-id pub-id-type="pmid">37209391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Egeberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kristensen</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Puig</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Garrelts</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>See</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Holzkaemper</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fotiou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>2263108</fpage>
            <pub-id pub-id-type="pmid">37781881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tillett</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Egeberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sonkoly</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gorecki</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tj&#x000e4;rnlund</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buyze</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wegner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McGonagle</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2023</year>
            <month>Sep</month>
            <day>15</day>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>169</fpage>
            <pub-id pub-id-type="pmid">37715294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kokolakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sabat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gomis-Kleindienst</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fritz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Burmester</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Ghoreschi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ohrndorf</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Effect of TNF-&#x003b1; Inhibitors on Nail Psoriasis and Psoriatic Arthritis-Real-World Data from Dermatology Practice.</article-title>
            <source>J Pers Med</source>
            <year>2021</year>
            <month>Oct</month>
            <day>25</day>
            <volume>11</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">34834435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luger</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Foehl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Molta</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Boggs</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>8</issue>
            <fpage>896</fpage>
            <page-range>896-904</page-range>
            <pub-id pub-id-type="pmid">19453794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Reich</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nestle</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Scher</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Guzzo</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>224</fpage>
            <page-range>224-31</page-range>
            <pub-id pub-id-type="pmid">18083272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walsh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Hoepken</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nurminen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mease</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4&#x000a0;years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.</article-title>
            <source>Clin Rheumatol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>12</issue>
            <fpage>3285</fpage>
            <page-range>3285-3296</page-range>
            <pub-id pub-id-type="pmid">30191421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kavanaugh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mease</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Krueger</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Gladman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gomez-Reino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Papp</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zrubek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mudivarthy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Visvanathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beutler</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.</article-title>
            <source>Arthritis Rheum</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>976</fpage>
            <page-range>976-86</page-range>
            <pub-id pub-id-type="pmid">19333944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reich</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arenberger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jazayeri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mrowietz</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Augustin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elewski</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Regnault</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Frueh</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study.</article-title>
            <source>Br J Dermatol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>184</volume>
            <issue>3</issue>
            <fpage>425</fpage>
            <page-range>425-436</page-range>
            <pub-id pub-id-type="pmid">32479641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gregoriou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsiogka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tsimpidakis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nicolaidou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kontochristopoulos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rigopoulos</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Treatment of nail psoriasis with brodalumab: an open-label unblinded study.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>e299</fpage>
            <page-range>e299-e301</page-range>
            <pub-id pub-id-type="pmid">33269501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Battista</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Scalvenzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martora</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Potestio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Megna</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments.</article-title>
            <source>Clin Cosmet Investig Dermatol</source>
            <year>2023</year>
            <volume>16</volume>
            <fpage>1899</fpage>
            <page-range>1899-1932</page-range>
            <pub-id pub-id-type="pmid">37519941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piaserico</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Riedl</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pavlovsky</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vender</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Mert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tangsirisap</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Haustrup</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gallo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brunner</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO).</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2023</year>
            <volume>10</volume>
            <fpage>1185523</fpage>
            <pub-id pub-id-type="pmid">37457564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kearns</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Uppal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chat</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Guidelines for the Use of Interleukin-17 Inhibitors for Psoriasis in the United States, Britain, and Europe: A Critical Appraisal and Comprehensive Review.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>55</fpage>
            <page-range>55-59</page-range>
            <pub-id pub-id-type="pmid">34804357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orbai</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Chakravarty</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shawi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Merola</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis.</article-title>
            <source>Dermatol Ther (Heidelb)</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>2859</fpage>
            <page-range>2859-2868</page-range>
            <pub-id pub-id-type="pmid">37713133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kristensen</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Keiserman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Papp</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>McCasland</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Eldred</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barcomb</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Behrens</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>81</volume>
            <issue>2</issue>
            <fpage>225</fpage>
            <page-range>225-231</page-range>
            <pub-id pub-id-type="pmid">34911706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simpson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kern</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Successful management of treatment resistant nail psoriasis with tildrakizumab.</article-title>
            <source>Australas J Dermatol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>390</fpage>
            <page-range>390-393</page-range>
            <pub-id pub-id-type="pmid">34114645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bourcier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sofen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fakharzadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wasfi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kerkmann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ghislain</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Poulin</surname>
                <given-names>Y</given-names>
              </name>
              <collab>PHOENIX 1 investigators</collab>
            </person-group>
            <article-title>Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.</article-title>
            <source>Br J Dermatol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>170</volume>
            <issue>2</issue>
            <fpage>398</fpage>
            <page-range>398-407</page-range>
            <pub-id pub-id-type="pmid">24117389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Igarashi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>H</given-names>
              </name>
              <collab>Japanese Ustekinumab Study Group</collab>
            </person-group>
            <article-title>Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.</article-title>
            <source>J Dermatol</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>242</fpage>
            <page-range>242-52</page-range>
            <pub-id pub-id-type="pmid">21955098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mokni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ameur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ghariani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sriha</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Belajouza</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Denguezli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nouira</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A Case of Nail Psoriasis Successfully Treated with Intralesional Methotrexate.</article-title>
            <source>Dermatol Ther (Heidelb)</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>647</fpage>
            <page-range>647-651</page-range>
            <pub-id pub-id-type="pmid">30255281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000fc;m&#x000fc;&#x0015f;el</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x000d6;zdemir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mevlito&#x0011f;lu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bodur</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>25</volume>
            <issue>9</issue>
            <fpage>1080</fpage>
            <page-range>1080-4</page-range>
            <pub-id pub-id-type="pmid">21118309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gooderham</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bachelez</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goncalves</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Crowley</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>74</volume>
            <issue>1</issue>
            <fpage>134</fpage>
            <page-range>134-42</page-range>
            <pub-id pub-id-type="pmid">26549249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roter</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Szczerkowska-Dobosz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nowicki</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Treatment of nail psoriasis with pulsed dye laser versus combined pulsed dye and Nd:YAG lasers-An intrapatient left-to-right study.</article-title>
            <source>Lasers Surg Med</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>54</volume>
            <issue>5</issue>
            <fpage>688</fpage>
            <page-range>688-692</page-range>
            <pub-id pub-id-type="pmid">35289430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Konisky</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Klinger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Coe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jaller</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kobets</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A focused review on laser- and energy-assisted drug delivery for nail disorders.</article-title>
            <source>Lasers Med Sci</source>
            <year>2024</year>
            <month>Jan</month>
            <day>19</day>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <pub-id pub-id-type="pmid">38240827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Afify</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Shaheen</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>El-Banna</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Fractional CO<sub>2</sub> laser in the treatment of nail psoriasis: how can it help?</article-title>
            <source>Arch Dermatol Res</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>315</volume>
            <issue>6</issue>
            <fpage>1705</fpage>
            <page-range>1705-1715</page-range>
            <pub-id pub-id-type="pmid">36809406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mastorino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baril&#x000e0;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cattel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Panzone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quaglino</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ribero</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dapavo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of nail psoriasis.</article-title>
            <source>Dermatol Ther</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>12</issue>
            <fpage>e15917</fpage>
            <pub-id pub-id-type="pmid">36214268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rusia</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Madke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jawade</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Coexistence of Trachyonychia and Mucocutaneous Lichen Planus: A Case Report.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>e48415</fpage>
            <pub-id pub-id-type="pmid">38073956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dube</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bhushan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Tofacitinib for the Treatment of Twenty-Nail Dystrophy: A Single Case Report.</article-title>
            <source>Indian J Dermatol</source>
            <year>2022</year>
            <season>Nov-Dec</season>
            <volume>67</volume>
            <issue>6</issue>
            <fpage>725</fpage>
            <page-range>725-727</page-range>
            <pub-id pub-id-type="pmid">36998870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baran</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>[How to diagnose and treat psoriasis of the nails].</article-title>
            <source>Presse Med</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>43</volume>
            <issue>11</issue>
            <fpage>1251</fpage>
            <page-range>1251-9</page-range>
            <pub-id pub-id-type="pmid">25443636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albrakati</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Alshareef</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Alhawsawi</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Al Hawsawi</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Atypical Juvenile Pityriasis Rubra Pilaris: A Case Report of Early Onset With Late Diagnosis.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>e30234</fpage>
            <pub-id pub-id-type="pmid">36381776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Husein-ElAhmed</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Husein-ElAhmed</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2023</year>
            <month>Jul</month>
            <day>21</day>
            <volume>48</volume>
            <issue>8</issue>
            <fpage>895</fpage>
            <page-range>895-902</page-range>
            <pub-id pub-id-type="pmid">37052062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rigopoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Baran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chiheb</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Di Chiacchio</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gregoriou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grover</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Haneke</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Iorizzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pasch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piraccini</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Richert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rompoti</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Singal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Starace</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tosti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Triantafyllopoulou</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Zaiac</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>228</fpage>
            <page-range>228-240</page-range>
            <pub-id pub-id-type="pmid">30731172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27962.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moreno-Romero</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Grimalt</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Nail Pitting in Psoriasis.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Nov</month>
            <day>29</day>
            <volume>379</volume>
            <issue>22</issue>
            <fpage>e39</fpage>
            <pub-id pub-id-type="pmid">30485773</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
